Tenderwize
Retour à la recherche

Open-house rebate agreements for Etanercept

AOK Bayern - Die Gesundheitskasse·München, Germany·Deadline Sep 05, 2026 · 7 days left·Open·Supplies·Framework
Inscrivez-vous pour sauvegarderOpen documents
Titre original de l'avis

Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Etanercept, ATC L04AB01

52/100

Score d'opportunité

Needs reviewMedium complexity
SuppliesFrameworkOpen
Pourquoi ce score ?

Opportunité

52 / 100

Complexité

58 / 100

Facteurs de risque

For paper submissions, the notice requires duplicate originals and a prior fax/scan/email/portal transmission only pres...

Participation is limited to pharmaceutical companies and requires a signed reliability self-declaration.

Submission deadline in 7 days

Analyse approfondie du portefeuille

Analyse approfondie de l'adéquation entreprise

Utilise:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Aperçu

Moderate opportunity

Faits clés

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until Oct 2026
  • Non-exclusive rebate agreements for the medicinal product Etanercept, ATC L04AB01.
  • Open-house model with identical, pre-set contract terms for all eligible pharmaceutical companies.
Afficher le résumé complet

Open-house supply arrangement for pharmaceutical products: non-exclusive rebate agreements for Etanercept (ATC L04AB01) offered by AOK Bayern to all interested pharmaceutical companies that meet the stated suitability requirement. This is explicitly described as a non-competitive open-house model with no selection decision and no negotiated terms. Contracting is possible throughout the term, with the latest contract conclusion date on 2026-09-05. Submission can be made electronically with a qualified electronic signature or in paper form; documents not in German must be submitted with a German translation.

Risques

For paper submissions, the notice requires duplicate originals and a prior fax/scan/email/portal transmission only pres...

Participation is limited to pharmaceutical companies and requires a signed reliability self-declaration.

Submission deadline in 7 days

L'analyse peut être incomplète

Seule une partie des documents de consultation a été analysée. Des exigences, certificats ou documents de soumission supplémentaires peuvent exister dans les documents restants.

Exigences clés

Eligibility

  • Only pharmaceutical companies are eligible as potential contract partners.

Administrative

  • Submission of a completed and signed self-declaration on reliability (Eigenerklärung zur Zuverlässigkeit).
  • Submission of the completed and signed contract and the completed and signed annex 'Festlegung der vertragsgegenständlichen Arzneimittel'.

Acheteur

Localisation

München, DEU

Site web

www.aok.de

Profil acheteur

Ouvrir le profil

Identifiant

DE811695320

Activité

Health

Lots (1)

LOT-0001

Open-house rebate agreements for Etanercept

Open-house supply lot for non-exclusive rebate agreements concerning the active substance Etanercept (ATC L04AB01). The notice states that all interested pharmaceutical companies meeting the suitability requirement may join on identical, non-individually negotiable terms. Place of performance is Germany, specifically DE212 (Bavaria/Munich region in the notice metadata).

SuppliesFrameworkEU fundedElectronic submission

Localisation

DE212, Germany

Durée

Oct 2024 - Oct 2026

Catégorie

Pharmaceutical products

Date limite

Deadline Sep 05, 2026

Détails de la procédure

Date de publication
16 Sep 2024
Langues
German

Métadonnées de référence

Base juridique
32014L0024

Identifiants de référence

ID de l'appel d'offres
557440-2024

Documents (2)

Document de consultation 1Portail de soumission 1

Appels d'offres similaires

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta

Aug 30